Full field digital mammography, performed instead of screen film mammography, finds fewer interval breast cancers.
The switch to full field digital mammography (FFDM) has changed the mammographic presentation of interval breast cancer, with fewer interval cancers presenting in association with microcalcifications, according to a study published in the European Journal of Radiology.
Researchers from Ireland sought to assess the impact of FFDM on the classification of interval breast cancers and to compare the mammographic features of interval cancers at FFDM and screen film mammography (SFM).
The researchers looked at 76 cases of interval breast cancer following FFDM screening and 62 following SFM screening. Five consultant breast radiologists assessed prior screening mammograms. The review classified cases as missed, minimal signs, occult, or true interval breast cancer. Mammographic features of the interval cancer at diagnosis and any abnormality identified on the prior screening mammogram were recorded.
The results showed that there was not much difference between FFDM and SFM for missed cancers, but there were significantly fewer interval cancers presenting as microcalcifications following SFM.
The interval breast cancers did not show up as frequently with FFDM, so this can be problematic, concluded the researchers.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.